Filtros de búsqueda

Lista de obras de

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center

artículo científico publicado en 2017

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

artículo científico publicado en 2011

A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results

artículo científico publicado en 2017

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

artículo científico publicado en 2013

A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas ⬇️

artículo científico publicado el 14 de abril de 2010

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

artículo científico publicado en 2015

Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

artículo científico publicado en 2019

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

scientific article published on 23 September 2020

Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma

artículo científico publicado en 2017

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan

artículo científico publicado en 2007

Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia

article

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

artículo científico publicado en 2008

Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation

artículo científico publicado en 2011

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

artículo científico publicado en 2015

Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement

Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

artículo científico publicado en 2009

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

artículo científico publicado en 2012

Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM

scientific article published on 01 October 2020

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

artículo científico publicado en 2014

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results

artículo científico publicado en 2016

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens

scientific article published on 11 January 2019

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

scientific article published on 22 March 2019

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

artículo científico publicado en 2012

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

artículo científico publicado en 2020

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation

artículo científico publicado en 2022

Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant

scientific article published on 16 July 2007

Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.

artículo científico publicado en 2008

Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease

artículo científico publicado en 2014

Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center

artículo científico publicado en 2012

Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease

artículo científico publicado en 2009

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

scientific article published on 20 May 2016

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma

artículo científico publicado en 2015

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

artículo científico publicado en 2015

Durable remission with salvage second autotransplants in patients with multiple myeloma

artículo científico publicado en 2011

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

artículo científico publicado en 2012

Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome

artículo científico publicado en 2014

Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion

artículo científico publicado en 2018

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

artículo científico publicado en 2015

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

artículo científico publicado en 2011

Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma

scientific article published on 01 June 2006

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

artículo científico publicado en 2018

Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia ⬇️

artículo científico publicado el 12 de octubre de 2010

Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

artículo científico publicado en 2012

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

artículo científico publicado en 2008

HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant

scientific article published on 23 January 2019

Haploidentical Transplants for Patients with Relapse After the First Allograft

artículo científico publicado en 2020

Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

artículo científico publicado en 2020

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

artículo científico publicado en 2010

High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation

artículo científico publicado en 2011

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2013

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

artículo científico publicado en 2017

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

artículo científico publicado en 2012

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

scientific article published on 22 July 2018

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis

artículo científico publicado en 2015

Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease

artículo científico publicado en 2017

Hyperacute GVHD: risk factors, outcomes, and clinical implications

artículo científico publicado en 2007

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity

scientific article published on 01 April 2020

Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis

artículo científico publicado en 2019

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

scientific article published on 11 February 2019

Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

artículo científico publicado en 2017

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2018

Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia

artículo científico publicado en 2020

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

artículo científico publicado en 2013

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

artículo científico publicado en 2009

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

artículo científico publicado en 2012

Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation

artículo científico publicado en 2013

Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.

artículo científico publicado en 2017

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

artículo científico publicado en 2010

Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.

artículo científico publicado en 2013

Lenalidomide after stem-cell transplantation for multiple myeloma

artículo científico publicado en 2012

Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome

artículo científico publicado en 2018

Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival

artículo científico publicado en 2017

Melphalan based autologous transplant in octogenarian multiple myeloma patients

article

Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2009

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

artículo científico publicado en 2019

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

artículo científico publicado en 2011

Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

artículo científico publicado en 2009

Nonmyeloablative stem cell transplantation for chronic myeloid leukemia

artículo científico publicado en 2004

Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation

scientific article published on 10 September 2019

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis

artículo científico publicado en 2019

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

artículo científico publicado en 2015

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

artículo científico publicado en 2015

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2016

Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction

artículo científico publicado en 2009

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

artículo científico publicado en 2017

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

artículo científico publicado en 2016

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

artículo científico publicado en 2015

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

artículo científico publicado en 2016

Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2013

Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

artículo científico publicado en 2013

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

artículo científico publicado en 2019

Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia

scientific article published on 26 June 2019

Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma

artículo científico publicado en 2017

Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.

artículo científico publicado en 2017

Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers

artículo científico publicado en 2013

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2017

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

artículo científico publicado en 2016

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

artículo científico publicado en 2015

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

artículo científico publicado en 2018

Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

scientific article published on 18 October 2018

Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma

artículo científico publicado en 2009

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

artículo científico publicado en 2016

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

artículo científico publicado en 2017

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

artículo científico publicado en 2016

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2012

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

artículo científico publicado en 2018

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2016

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia

artículo científico publicado en 2016

Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant ⬇️

artículo científico publicado el 5 de diciembre de 2011

Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma

artículo científico publicado en 2010

Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

artículo científico publicado en 2016

Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes

artículo científico publicado en 2007

Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma

artículo científico publicado en 2006

Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia

artículo científico publicado en 2005

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma

artículo científico publicado en 2006

Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma

artículo científico publicado en 2014

Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission

artículo científico publicado en 2012

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

artículo científico publicado en 2014

Steroid-Refractory Acute GVHD: Predictors and Outcomes.

artículo científico publicado en 2011

The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation

artículo científico publicado en 2013

The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2014

The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes

artículo científico publicado en 2010

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

artículo científico publicado en 2011

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma

artículo científico publicado en 2017

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda